Evidence map›Paper›PMID 23165123›Full record

ReviewNature reviews. Clinical oncology2013

Predicting outcomes in radiation oncology--multifactorial decision support systems.

Philippe Lambin, Ruud G P M van Stiphout, Maud H W Starmans, Emmanuel Rios-Velazquez, Georgi Nalbantov, Hugo J W L Aerts, Erik Roelofs, Wouter van Elmpt, Paul C Boutros, Pierluigi Granone and 4 more

Registry-linked trialAbstract readReview
In one paragraph

Review in Nature reviews. Clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02851329 (Association of Computed Tomography Phenotypic Signature With Progression-free Survival in Stage IV EGFR-mutant Non-small Cell Lung Cancer Undergoing Tyrosine Kinase Inhibitors), which is not on this map. Cited by 168 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
168citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02851329 unknown statusnot on this mapstarted 2015, after this paper: background citation

Association of Computed Tomography Phenotypic Signature With Progression-free Survival in Stage IV EGFR-mutant Non-small Cell Lung Cancer Undergoing Tyrosine Kinase Inhibitors

TypeobservationalSponsorChinese Academy of SciencesRan2015 to 2017Enrolled500ConditionsNon-small Cell Lung Cancer
3 · Its place in the literature

Who cites it

168 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Inclusion of dosimetric data as covariates in toxicity-related radiogenomic studies : A systematic review.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2018
    Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Knowledge-Informed Machine Learning for Cancer Diagnosis and Prognosis: A Review.IEEE transactions on automation science and engineering : a publication of the IEEE Robotics and Automation Society · 2025
    Article

108 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Philippe LambinDepartment of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, 6229 ET, The Netherlands. philippe.lambin@maastro.nl
Ruud G P M van Stiphout
Maud H W Starmans
Emmanuel Rios-Velazquez
Georgi Nalbantov
Hugo J W L Aerts
Erik Roelofs
Wouter van Elmpt
Paul C Boutros
Pierluigi Granone
Vincenzo Valentini
Adrian C Begg
Dirk De Ruysscher
Andre Dekker

Funding

Radiomics of NSCLCU01CA143062 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI GILLIES, ROBERT J., SCHABATH, MATTHEW B. · 2010 to 2020
$5.7M
NCI NIH HHS U01 CA143062
6 · The paper itself

Abstract

With the emergence of individualized medicine and the increasing amount and complexity of available medical data, a growing need exists for the development of clinical decision-support systems based on prediction models of treatment outcome. In radiation oncology, these models combine both predictive and prognostic data factors from clinical, imaging, molecular and other sources to achieve the highest accuracy to predict tumour response and follow-up event rates. In this Review, we provide an overview of the factors that are correlated with outcome-including survival, recurrence patterns and toxicity-in radiation oncology and discuss the methodology behind the development of prediction models, which is a multistage process. Even after initial development and clinical introduction, a truly useful predictive model will be continuously re-evaluated on different patient datasets from different regions to ensure its population-specific strength. In the future, validated decision-support systems will be fully integrated in the clinic, with data and knowledge being shared in a standardized, instant and global manner.

Indexed as

Decision Support Systems, ClinicalModels, TheoreticalPrecision MedicineRadiation OncologyHumansNeoplasmsTreatment Outcome

Identifiers

PMID23165123
PMCPMC4555846

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.